Uveitis Therapy: The Corticosteroid Options

Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14(5–6):303–8.

Nguyen QD, Callanan D, Dugel P, et al. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage: proceedings of an expert panel roundtable discussion. Retina. 2006;26(8):1–16.

Barnes PJ. Glucocorticosteroids. Handb Exp Pharmacol. 2017;237:93–115.

Adcock IM, Mumby S. Glucocorticoids. Handb Exp Pharmacol. 2017;237:171–96.

Doughty M. Chapter 9-Ophthalmic corticosteroids: management of the ocular inflammatory response. Ocular pharmacology and therapeutics: a primary care guide. Philadelphia: Butterworth-Heinemann; 2001.

Cantrill HL, Palmberg Zink HA, Waltman SR, Podos SM, Becker B. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol. 1975;79:1012–7.

Mcghee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids. Drug Saf. 2002;25(1):33–55.

Sheppard J, Foster C, Toyos M, Markwardt K, Da Vanzo R, Flynn T, Kempen J. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: pooled efficacy analysis of two phase 3 studies. Ocul Immunol Inflamm. 2019;27(3):484–96.

Wilson ME, O’Halloran H, VanderVeen D, et al. Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. Eye (Lond). 2016;30(9):1187–94.

Slabaugh MA, Herlihy E, Ongchin S, van Gelder RN. Efficacy and potential complications of difluprednate use for pediatric uveitis. Am J Ophthalmol. 2012;153:932–8.

McKay KM, Borkar DS, Sevgi DD, Susarla G, Papaliodis GN, Sobrin L. Comparison of modified posterior sub-tenon’s vs trans-septal triamcinolone injection for non-infectious uveitis. Ocul Immunol Inflamm. 2020;4:1–8 (Epub ahead of print).

Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112(11):1916–7.

Park UC, Park JH, Yu HG. Long-term outcome of intravitreal triamcinolone acetonide injection for the treatment of uveitis attacks in Behcet disease. Ocul Immunol Inflamm. 2014;22(1):27–33.

Kramer M, Ehrlich R, Snir M, et al. Intravitreal injections of triamcinolone acetonide for severe vitritis in patients with incomplete Behcet’s disease. Am J Ophthalmol. 2004;138(4):666–7.

Tuncer S, Yilmaz S, Urgancioglu M, Tugal-Tutkun I. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behcet disease. J Ocul Pharmacol Ther. 2007;23(4):395–401.

Ohguro N, Yamanaka E, Otori Y, Saishin Y, Tano Y. Repeated intravitreal triamcinolone injections in Behcet disease that is resistant to conventional therapy: 1-year results. Am J Ophthalmol. 2006;141(1):218–20.

Ozdemir H, Karacorlu M, Karacorlu S. Intravitreal triamcinolone acetonide in sympathetic ophthalmia. Graefes Arch Clin Exp Ophthalmol. 2005;243(7):734–6.

Jonas JB, Spandau UH. Repeated intravitreal triamcinolone acetonide for chronic sympathetic ophthalmia. Acta Ophthalmol Scand. 2006;84(3):436.

Chan RV, Seiff BD, Lincoff HA, Coleman DJ. Rapid recovery of sympathetic ophthalmia with treatment augmented by intravitreal steroids. Retina. 2006;26(2):243–7.

Jonas JB. Intravitreal triamcinolone acetonide for treatment of sympathetic ophthalmia. Am J Ophthalmol. 2004;137(2):367–8.

Karacorlu M, Arf Karacorlu S, Ozdemir H. Intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada syndrome. Eur J Ophthalmol. 2006;16(3):481–3.

Andrade RE, Muccioli C, Farah ME, Nussenblatt RB, Belfort R Jr. Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 2004;137(3):572–4.

Moreker MR, Lodhi SA, Pathengay A. Role of intravitreal triamcinolone as an adjuvant in the management of Vogt-Koyanagi-Harada disease. Indian J Ophthalmol. 2007;55(6):479–80.

Shin JY, Yu HG. Intravitreal triamcinolone injection for uveitic macular edema: a randomized clinical study. Ocul Immunol Inflamm. 2015;23(6):430–6.

Ganapathy PS, Lowder CY, Arepalli S, Baynes K, Li M, Bena J, Srivastava SK. Treatment duration and side effect profile of long-term use of intravitreal preservative-free triamcinolone acetonide in uveitis. Am J Ophthalmol. 2018;194:63–71.

Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther. 2004;20(3):269–75.

Sugar EA, Holbrook JT, Multicenter Uveitis Steroid Treatment Trial Research G, et al. Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis. Ophthalmology. 2014;121(10):1855–62.

Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113(6):1020–7.

Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW, Fluocinolone Acetonide Study G. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology. 2010;117(3):567–75.

Kempen JH, Altaweel MM, Multicenter Uveitis Steroid Treatment Trial Research Group, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118(10):1916–26.

Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: 3-year clinical trial results. Arch Ophthalmol. 2008;126(9):1191–201.

Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 2005;112(7):1192–8.

Kempen JH. Randomized, controlled, prospective assessment of the safety of systemic therapy for uveitis: 7-year results of the must trial and follow-up study. In: Abstract presented at American Academy of Ophthalmology Uveitis Subspecialty Meeting. 2016.

Kempen JH, Altaweel MM, Multicenter Uveitis Steroid Treatment Trial Research G, et al. Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: 54-month results of the multicenter uveitis steroid treatment (MUST) trial and follow-up study. Ophthalmology. 2015;122(10):1967–75.

Yeh S, Cebulla CM, Witherspoon SR, et al. Management of fluocinolone implant dissociation during implant exchange. Arch Ophthalmol. 2009;127(9):1218–21.

Nicholson BP, Singh RP, Sears JE, Lowder CY, Kaiser PK. Evaluation of fluocinolone acetonide sustained release implant (Retisert) dissociation during implant removal and exchange surgery. Am J Ophthalmol. 2012;154(6):969–73.

Chang PY, Kresch Z, Samson CM, Gentile RC. Spontaneous dissociation of fluocinolone acetonide sustained release implant (Retisert) with dislocation into the anterior chamber. Ocul Immunol Inflamm. 2015;23(6):454–7.

Holbrook JT, Sugar EA, Burke AE, et al. Dissociations of the fluocinolone acetonide implant: The Multicenter Uveitis Steroid Treatment (MUST) trial and follow-up study. Am J Ophthalmol. 2016;164:29–36.

Itty S, Callanan D, Jones R, Pecen P, Martel J, Jaffe GJ. Spontaneous dislocation of fluocinolone acetonide implant pellets from their suture struts. Am J Ophthalmol. 2015;159(5):868–76.

Agency MaHPR. Illuvien 190 micrograms intravitreal implant in applicator: summary of product characteristics. 2012.

Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583–7.

Pouwels XGLV, Petersohn S, Carrera VH, et al. Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis: an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics. 2019 Nov 8. (Epub ahead of print).

El-Ghrably IA, Saad A, Dinah C. A novel technique for repositioning of a migrated ILUVIEN® (fluocinolone acetonide) implant into the anterior chamber. Ophthalmol Ther. 2015;4(2):129–33.

Lam WC, Albiani DA, Yoganathan P, et al. Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study. Clin Ophthalmol. 2015;9:1255–68.

Chang-Lin JE, Burke JA, Peng Q, et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Investig Ophthalmol Vis Sci. 2011;52(7):4605–9.

Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545–53.

Khurana RN, Bansal AS, Chang LK, Palmer JD, Wu C, Wieland MR. Prospective evaluation of a sustained-release dexamethasone intravitreal implant for cystoid macular edema in quiescent uveitis. Retina. 2017;37(9):1692–9.

Pichi F, Nucci P, Baynes K, Lowder CY, Srivastava SK. Sustained-release dexamethasone intravitreal implant in juvenile idiopathic arthritis-related uveitis. Int Ophthalmol. 2017;37(1):221–8.

Tsang AC, Virgili G, Abtahi M, Gottlieb CC. Intravitreal dexamethasone implant for the treatment of macular edema in chronic non-infectious uveitis. Ocul Immunol Inflamm. 2017;25(5):685–92.

Majumder PD, Palkar AH, Pathare N, Biswas J. Anterior chamber migration of a sustained-release dexamethasone intravitreal implant: a case report and review of literature. Oman J Ophthalmol. 2019;12(2):133–7.

Jaffe GJ, Lin P, Keenan RT, et al. Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis. Ophthalmology. 2016;123:1940–8.

Jaffe GJ, Foster CS, Pavesio CE, Paggiarino DA, Riedel GE. Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: 12-month results. Ophthalmology. 2019;126:601–10.

Kuppermann BD, Zacharias LC, Kenney MC. Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2014;112:116–41.

Patel SR, Berezovsky DE, McCarey BE, Zarnitsyn V, Edelhauser HF, Prausnitz MR. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Investig Ophthalmol Vis Sci. 2012;53(8):4433–41.

Patel S, Lin A, Edelhauser H, Prausnitz M. Suprachoroidal drug delivery to the back of the eye using hollow needles. Pharm Res. 2011;28(1):166–76.

Olsen TW, Feng X, Wabner K, Conston SR, Sierra DH, Folden DV, Smith ME, Cameron JD. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am J Ophthalmol. 2006;142(777):787.

Goldstein DA, Do D, Noronha G, Kissner JM, Srivastava SK, Nguyen QD. Suprachoroidal corticosteroid administration: a novel route for local treatment of noninfectious uveitis. Transl Vis Sci Technol. 2016;5(6):14.

Yeh S, et al. Suprachoroidal injection of triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis: a randomized, phase 2 Study (DOGWOOD). Retina. 2019;39:1880–8.

Yeh S, et al. Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3, randomized trial. Ophthalmology. (In press).

Wykoff CC, Khurana RN, Lampen SIR, Noronha G, Brown DM, Ou WC, et al. Suprachoroidal triamcinolone acetonide for diabetic macular edema: the HULK trial. Ophthalmol Retina. 2018;2:874–7.

Charkoudian LD, Ying GS, Pujari SS, et al. High-dose intravenous corticosteroids for ocular inflammatory diseases. Ocul Immunol Inflamm. 2012;20(2):91–9.

Jabs DA. Immunosuppression for the uveitides. Ophthalmology. 2017;20:31557–9.

Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, Van der Heijden GJ. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68(12):1833–8.

Skalka HW, Prchal JT. Effect of corticosteroids on cataract formation. Ophthalmology. 1980;98:1773–7.

Dibas A, Yorio T. Glucocorticoid therapy and ocular hypertension. Eur J Pharmacol. 2016;787:57–71.

Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye. 2006;20:407–16.

Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same? Ophthalmol Ther. 2013;2(2):55–72.

Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–32.

Chan A, Leung LS, Blumenkranz MS. Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion. Clin Ophthalmol. 2011;5:1043–9.

Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion 12-month study results. Ophthalmology. 2011;118(12):2453–60.

Bahadorani S, Krambeer C, Wannamaker K, et al. The effects of repeated Ozurdex injections on ocular hypertension. Clin Ophthalmol. 2018;12:639–42.